GlassScriptPhysician profile
Phillip Reid
NPI 1093703969
$2,092.26
in general payments reported to CMS, 2019-2025
44 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.67 · 2020: $27.89 · 2021: $13.90 · 2022: $566 · 2023: $452 · 2024: $597 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.97 |
| Education | $116.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $285.09 | 2022 | |
| Daiichi Sankyo INC. | $162.65 | 2022-2024 | Enhertu |
| Aveo Pharmaceuticals, INC. | $156.22 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $137.44 | 2020-2023 | Xpovio |
| Epizyme, INC. | $125.00 | 2022 | |
| Pfizer INC. | $99.10 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $75.38 | 2021-2024 | |
| Astellas Pharma US INC | $71.15 | 2023-2025 | Xtandi, Xospata, Padcev |
| Celgene Corporation | $68.40 | 2023-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $64.37 | 2023-2025 | Opdualag, Krazati |
| Regeneron Healthcare Solutions, INC. | $62.52 | 2024 | Libtayo |
| Genentech USA, INC. | $52.39 | 2023-2025 | Polivy, Venclexta, Phesgo |
| Abbvie INC. | $52.22 | 2025 | |
| Mirati Therapeutics, INC. | $43.32 | 2024 | Krazati |
| Glaxosmithkline, LLC. | $43.01 | 2023-2025 | Ojjaara, Zejula, Jemperli |
Show all 42 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.